- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
In this phase 3b, open-label, controlled trial, adult participants with obesity but without type 2 diabetes were randomly assigned in a 1:1 ratio to receive the maximum tolerated dose of
- Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease . . .
Targeted DNA Methylation Using Modified DNA Probes: A Potential Therapeutic Tool for Depression and Stress-Related Disorders, International Journal of Molecular Sciences, 26, 12, (5643), (2025
- Recently Published - The New England Journal of Medicine
Explore this issue of The New England Journal of Medicine (Vol 0 No 0)
- Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal . . .
Tezepelumab is a human monoclonal antibody that specifically blocks TSLP from interacting with its heterodimeric receptor 21,22 Tezepelumab administered subcutaneously at a dose of 210 mg every 4
- Lepodisiran - The New England Journal of Medicine
Elevated lipoprotein(a) concentrations are associated with atherosclerotic cardiovascular disease The safety and efficacy of lepodisiran, an extended-duration, small interfering RNA targeting hepa
- Zongertinib in Previously Treated - The New England Journal of Medicine
In cohort 1, a total of 75 patients received zongertinib at a dose of 120 mg At the data cutoff (November 29, 2024), 71% of these patients (95% confidence interval [CI], 60 to 80; P<0 001 against
- The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
- Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Despite treatment advances in lupus nephritis, including regulatory approvals of belimumab and voclosporin, 1,2 the goal to sufficiently improve short- and long-term outcomes in patients with
|